Endeavor BioMedicines, a clinical-stage biotech company focused on life-threatening diseases, announced that its investigational therapy taladegib (ENV-101) has been granted Orphan Drug Designation by both the U.S. Food and Drug Administration (FDA) and the European Commission (EC) for the treatment of idiopathic pulmonary fibrosis (IPF).
IPF is a rare, progressive lung disease with limited treatment options and no known cure. Taladegib, a Hedgehog pathway inhibitor, is currently being evaluated in the Phase 2b WHISTLE-PF clinical trial, which aims to assess its potential to reverse disease progression. Patient enrollment is underway and is expected to be completed in 2026.
“Receiving Orphan Drug Designation in both the U.S. and EU underscores the urgent need for new therapies in IPF,” said Dr. Lisa Lancaster, Chief Medical Officer of Endeavor. “We are optimistic about taladegib’s potential to go beyond symptom management and actually alter the course of the disease.”
Orphan Drug Designation provides a range of benefits to drug developers. In the U.S., these include tax credits for clinical development, user fee waivers, and up to seven years of market exclusivity upon approval. In the EU, the designation offers 10 years of market exclusivity, reduced regulatory fees, and access to protocol assistance.
The WHISTLE-PF trial is part of Endeavor’s broader strategy to bring novel, disease-modifying therapies to patients with severe and underserved conditions.